34 results about "Plasma exposure" patented technology

The present invention provides a tetrazole compound, a pharmaceutical composition thereof and a use thereof. The compound of the present invention has a brand-new structure, a low clearance rate, high plasma exposure, good oral bioavailability, and good pharmacokinetic properties, and is conducive to drug development. The compound of the present invention or a pharmaceutically acceptable salt thereof can be used for preventing and / or treating pain, including neuropathic pain, etc.

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

Relacorilant is useful in the treatment of hypercortisolism and cancer. Many drugs useful in treating hypercortisolism or cancer are metabolized by CYP2C9 enzymes. The effects of concomitant administration of relacorilant and a CYP2C9 substrate are disclosed herein.Relacorilant potently inhibited CYP2C9 in an in vitro test, indicating that co-administration of relacorilant and a CYP2C9 substrate would be expected to increase the CYP2C9 substrate plasma exposure more than five-fold in vivo. Significant reductions in CYP2C9 substrate doses would be expected to be required when administered with relacorilant.Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of a CYP2C9 substrate such as, e.g., tolbutamide, glimepiride, and glipizide. Relacorilant and unmodified doses of CYP2C9 substrate such as tolbutamide, glimepiride, and glipizide may be co-administered to treat hypercortisolism, or may be co-administered to a cancer patient.

Provided are methods for increasing the deposition rate and improving the film properties of silicon-containing films via plasma-enhanced atomic layer deposition (PEALD) by utilization of hydrogen peroxide. In particular, an exposure to hydrogen peroxide before, during, or after the plasma exposure step of a low temperature PEALD process utilizing silicon-containing compounds results in increased deposition rates and superior film characteristics as compared to PEALD processes using plasma alone. Additionally, the disclosed process may utilize non-oxidizing plasmas, increasing the range of substrates to which the process can be applied relative to those compatible with oxidizing plasmas.

Articles may include at least non-PFAS elastomers and additives. The non-PFAS elastomers may include at least one of polyacrylate elastomer (ACM), polyethylene acrylate elastomer (AEM), ethylene propylene diene monomers (EPDM) elastomer, ethylene propylene monomers (EPM), nitrile butadiene rubbers (NBR) and hydrogenated nitrile butadiene rubbers (HNBR) elastomer. Under a six-hour remote NF3 plasma exposure at 150° C., the non-PFAS elastomers may have a weight change less than or equal to about 2%. The additives may include fillers, which include at least one of carbon black, silicon carbide, silica, barium sulfate, carbon, clay, talc, metallic fillers, metallic nitrides, and / or organic fillers. The organic fillers may include polyether ether ketone (PEEK), polyaryl ether ketone (PAEK), or nylon. The non-PFAS elastomer may have a weight percentage from about 25% to about 99%. The additives have a weight percentage from about 1% to about 67%.

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma. CSF, and / or brain exposure of sepiapterin.

The invention provides a GK001 solid preparation as well as a preparation method and application thereof. The solid preparation comprises the following components: a GK001 amorphous solid dispersion, an excipient, a diluent, a disintegrating agent and a lubricant, the GK001 has a structure as shown in a formula I which is described in the specification. According to the invention, GK001 is creatively prepared into a solid preparation in the form of amorphous solid dispersion, and the solid preparation has excellent stability and fluidity and high oral availability. The preparation is moderate in hardness and stable in quality, the process requirements are met, and the friability and disintegration time limit both meet the requirements; the dissolution rate of the preparation is basically consistent with the drug content, the plasma exposure is high, and the oral dose of the drug and the plasma exposure are in a linear relationship.

Articles may include at least non-PFAS elastomers and additives. The non-PFAS elastomers may include at least one of polyacrylate elastomer (ACM), polyethylene acrylate elastomer (AEM), ethylene propylene diene monomers (EPDM) elastomer, ethylene propylene monomers (EPM), nitrile butadiene rubbers (NBR) and hydrogenated nitrile butadiene rubbers (HNBR) elastomer. Under a six-hour remote NF3 plasma exposure at 150°C, the non-PFAS elastomers may have a weight change less than or equal to about 2%. The additives may include fillers, which include at least one of carbon black, silicon carbide, silica, barium sulfate, carbon, clay, talc, metallic fillers, metallic nitrides, and / or organic fillers. The organic fillers may include polyether ether ketone (PEEK), polyaryl ether ketone (PAEK), or nylon. The non-PFAS elastomer may have a weight percentage from about 25% to about 99%. The additives have a weight percentage from about 1% to about 67%.

To provide methods of treating BH4-related disorders such as CNS disorder.SOLUTION: A method comprises a step for administering to a subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, without food. Preferably, the effective method should be an amount sufficient to produce a concentration of at least 0.5 ng / mL in a plasma of the subject within one hour of administration.SELECTED DRAWING: None

This application relates to the field of pharmaceutical technology, and in particular to a topical ointment formulation and its preparation method. The formulation uses Sonicate as the active ingredient, combined with petrolatum, liquid paraffin, a solubilizing and penetration-enhancing system, and emulsifiers as excipients, to form an O / W type cream, an oil-based or water-soluble ointment. The preparation process employs a low-temperature dosing method at 40°C to ensure drug activity and inhibit crystallization. This application achieves high-concentration retention in local skin tissue through topical administration, significantly reducing radiation damage scores and pathological damage, while resulting in extremely low systemic plasma exposure, avoiding the systemic toxicity of oral administration, and providing a safe and efficient means for the clinical prevention and treatment of radiation-induced skin damage.

In one aspect, the disclosure relates to a method for modifying or treating a cellulose material, comprising: combining a cellulose feedstock and a first solvent, thereby forming a cellulosic suspension; mixing the cellulosic suspension under high shear; and treating the cellulosic suspension with a reaction treatment comprising: incubation of the cellulosic suspension at a temperature of at least 30°C; microwave irradiation exposure; plasma exposure; ultrasound exposure; grinding; ball-milling; extrusion; a sequence thereof; or any combination thereof. In another aspect, the disclosure relates to compositions produced by the methods disclosed herein. In another aspect, the disclosure relates to filaments, yarns, films, sheets, cast materials, molded materials, articles, and any combination thereof comprising the compositions produced by the methods disclosed herein. In addition, the disclosure provides for compositions, fibers, filaments, yarns, casts, molds, articles, clothing, and the like, that include the modified or treated cellulose.

The application discloses a levodopa plasma exposure reconstruction and pharmacokinetics inference method, system, device and storage medium based on multi-body fluid observation fusion and capillary blood anchor updating, the application breaks through the limitation of single body fluid observation through multi-body fluid observation fusion, can more comprehensively and accurately obtain the relevant information of levodopa in the body, provides more abundant and accurate data support for plasma exposure reconstruction, secondly, the capillary blood anchor updating mechanism can calibrate and update the related data in real time and dynamically, ensure the accuracy and timeliness of plasma exposure reconstruction, the combination of multi-body fluid observation fusion and capillary blood anchor updating mechanism innovation effectively improves the accuracy of levodopa plasma exposure reconstruction and the reliability of pharmacokinetics inference, can better assist medical personnel to understand the metabolism of levodopa in the patient's body, has important clinical application value and broad market prospect.

Methods of forming SiCON films comprising sequential exposure to a silicon precursor and a mixture of alkanolamine and amine reactants and an optional plasma are described. Methods of forming a silicon-containing film comprising sequential exposure to a silicon precursor and an epoxide with an optional plasma exposure are also described.

The present invention provides a method, apparatus, and medium for oxidizing features formed on a half-dimensional device structure. [Solution] Suitable for use in semiconductor manufacturing. The oxide layer is formed by exposing the substrate to both high-pressure oxidizing agent exposure and low-pressure oxygen-containing plasma exposure. High-pressure oxidizing agent exposure is performed at a pressure exceeding 10 Torr, and low-pressure oxygen-containing plasma exposure is performed at a pressure of less than approximately 10 Torr. Features are high aspect ratio trenches or holes in a stack of silicon oxide and silicon nitride layers.

The present invention presents pharmaceutical compositions comprising sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for treating BH4-related disorders. In some embodiments, these compositions and methods result in increased plasma exposure to BH4.

Provided are methods for increasing the deposition rate and improving the film properties of silicon-containing films via plasma-enhanced atomic layer deposition (PEALD) by utilization of hydrogen peroxide. In particular, an exposure to hydrogen peroxide before, during, or after the plasma exposure step of a low temperature PEALD process utilizing silicon-containing compounds results in increased deposition rates and superior film characteristics as compared to PEALD processes using plasma alone. Additionally, the disclosed process may utilize non-oxidizing plasmas, increasing the range of substrates to which the process can be applied relative to those compatible with oxidizing plasmas.

A compound, a chelate and the use thereof in magnetic resonance imaging, belonging to the technical field of medical imaging. Specifically disclosed is a compound as represented by general formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, which can significantly increase plasma exposure, has high bioavailability, can prolong an in vivo imaging time window, and has the advantages of long-acting and low-dose imaging. The present invention also has good clearance characteristics and low risk of tissue residues, thereby reducing the potential risk of release of free Gd3+, and providing a long-acting, low-dose and high-safety magnetic resonance contrast solution for clinical use.

The invention relates to the technical field of quartz sand preparation, and particularly discloses a plasma method preparation process of high-purity quartz sand, which comprises the following steps: 1, pretreating raw materials, crushing common quartz sand until the particle size is 50-200mu m, washing with water to remove silt, and drying until the water content is less than or equal to 0.5%; the vertical gas-solid fluidized bed reactor is adopted, the plasma exposure path of quartz sand particles is prolonged through a spiral flow channel reaction cavity of the vertical gas-solid fluidized bed reactor, argon plasma can make full contact with the surfaces of the particles within the suspension heating treatment time of 0.1-10 s, metal impurities on the surfaces are effectively removed, multiple stages of plasma nozzles are arranged in a layered mode in the axial direction of a spiral flow channel, and therefore the effect of improving the stability of the gas-solid fluidized bed reactor is achieved. And in cooperation with a segmented temperature control mode, the first temperature zone removes organic matter and volatile metal impurities adsorbed on the surface, and the second temperature zone pushes gasification of metal oxides through thermodynamic equilibrium, so that deep impurities are further removed.

The application discloses a compound, a preparation method thereof and application of the compound in a diagnostic agent, and belongs to the technical field of medical imaging. The application specifically discloses a compound as shown in the formula (I) or a stereoisomer, a pharmaceutically acceptable salt or a mixture thereof, which can significantly improve plasma exposure, has high bioavailability, can prolong an in-vivo imaging time window, has the advantages of long-acting and low-dose imaging, and has good clearance characteristics and low tissue residual risk, so that free Gd 3+ is released, hidden dangers are reduced, and a long-acting, low-dose and high-safety magnetic resonance contrast solution is provided for the clinic.

The present invention provides a solid dispersion, its preparation method and use, which comprises an active ingredient, a compound of Formula A or a derivative thereof, in a crystalline form, an amorphous form, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a carrier. The solid dispersion can significantly improve the oral bioavailability of the active ingredient, has good solid-state stability, and allows the active ingredient to exhibit high plasma exposure in rats.

A method and apparatus for growing an oxide layer within a feature of a substrate is described herein. The method is suitable for use in semiconductor manufacturing. The oxide layer is formed by exposing a substrate to both a high pressure oxidant exposure and a lower pressure oxygen containing plasma exposure. The high pressure oxidant exposure is performed at a pressure of greater than 10 Torr, while the lower pressure oxygen containing plasma exposure is performed at a pressure of less than about 10 Torr. The features are high-aspect ratio trenches or holes within a stack of silicon oxide and silicon nitride layers.

The invention relates to the technical field of plasma application, in particular to a plasma grain disinfecting and killing device based on creeping discharge. The device comprises a conveyor belt system, a high-voltage electrode, a grounding electrode, a nanosecond pulse power supply module, an electric control unit and a safety protection structure. High-voltage electrodes and grounding electrodes which are arranged in a staggered manner and embedded in a coplanar manner are arranged on the surface of the conveying belt to form a micro-slope electrode structure; under the excitation of high voltage, surface discharge plasma and gliding wind are generated, and the thrust of the ion wind is utilized to cooperate with the electrode layout, so that the seeds automatically roll in the conveying process, and multi-angle and all-directional plasma exposure and disinfection treatment are realized. The device solves the problems of uneven treatment, low efficiency, thermal damage or chemical residues and the like in the prior art, has the advantages of uniform treatment, environment friendliness, simplified structure, high adaptability and the like, and is particularly suitable for continuous online sterilization and preservation of grain seeds.

Relacorilant is a selective modulator of the type II glucocorticoid receptor (GR); it may be orally administered. Applicant discloses in vitro studies that show relacorilant to be a potent inhibitor of P-glycoprotein (P-gp). Surprisingly, in vivo studies of co-administration of relacorilant and dabigatran etexilate (a P-gp substrate) showed that relacorilant had minimal-to-no impact on the free and total dabigatran plasma exposures, suggesting that only minimal or no dose adjustments are needed for P-gp substrates upon coadministration with relacorilant. The surprising finding that relacorilant may be safely co-administered with P-gp substrates without need for significant dose adjustment provides improved methods and uses for treatment of such disorders as, for example, hypercortisolism (e.g., Cushing's syndrome, Cushing's Disease), hyperglycemia, hypertension, and a solid tumor in combination with chemotherapy or immunotherapy agents.

Provided are a prodrug of a small molecule compound having a naphthylamine structure and the use thereof, wherein the prodrug is as shown in the following formula I. The provided prodrug of the small molecule compound having the naphthylamine structure has good stability and permeability, and a high oral bioavailability. Compared with the parent drug compound I-1, the prodrug exhibits improved plasma exposure, or a prolonged residence time with a higher AUC after administration. Furthermore, the prodrug has high safety with fewer adverse reactions, and a strong drug development potential.

The utility model discloses a plasma centrifugal flow rate detection structure belongs to blood product production technical field. The structure includes centrifuge, flow rate measurement container and buffer bucket, and the liquid inlet of flow rate measurement container is passed through the liquid outlet pipeline and is communicated with the supernatant liquid outlet of centrifuge, and the liquid inlet of buffer bucket is communicated with the liquid outlet of flow rate measurement container through temperature measurement component. The whole supernatant liquid outlet temperature and liquid outlet flow rate detection of centrifuge are all completed in the closed environment, do not need to dismount liquid outlet pipeline or dismount other components, and the operation is simple, avoids the risk that plasma splashes to the ground, avoids the plasma exposure in the external environment simultaneously, and the risk of plasma being contaminated is reduced significantly.

This invention discloses a compound, a chelate, a method for preparing the same, and its application in the preparation of magnetic resonance imaging contrast agents, belonging to the field of medical imaging technology. Specifically, this invention discloses a compound as shown in formula (I) or its stereoisomers, pharmaceutically acceptable salts, or mixtures thereof, which can significantly increase plasma exposure, has high bioavailability, and can prolong the in vivo imaging time window, possessing the advantages of long-acting, low-dose imaging; it also has good clearance properties and a low risk of tissue residue, thereby reducing free Gd. 3+ This approach aims to eliminate potential risks and provide a long-lasting, low-dose, and highly safe magnetic resonance imaging (MRI) contrast solution for clinical use.

The present invention relates to the field of chemical pharmaceutics, relates to a lipoprotein (a) inhibitor, and specifically provides a compound having a structure as represented by formula (0), or an isomer, isotopically labeled compound or prodrug thereof, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof. The present invention exhibits a greater inhibitory activity against Lp(a) assembly and oxidized phospholipid-apolipoprotein(a), and better PK (oral bioavailability, and plasma exposure and hepatic exposure of a drug).

Methods of forming SiCON films comprising sequential exposure to a silicon precursor and a mixture of alkanolamine and amine reactants and an optional plasma are described. Methods of forming a silicon-containing film comprising sequential exposure to a silicon precursor and an epoxide with an optional plasma exposure are also described.

A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours. Methods of elevating 5-HTP plasma exposure are also described.

The invention relates to a method for manufacturing a mixed metal / composite battery tray. The present disclosure teaches a method of manufacturing a mixed metal / composite battery tray. A possibly deep hybrid tray may be made from a metal cross-shaped partial tray having four polymer / fiber composite rounded corner inserts attached to the partial tray recessed corners. The overlapping bond joints may be co-molded. The overlay metal bonding surface may be pretreated by laser ablation and / or plasma exposure to increase bonding strength between the overlay metal and the polymer / fiber composite surface. Joint strength may be increased with a mechanical interlocking feature. The mixed metal / composite tray can be manufactured by press-forming different components with a molding tool and a press. Four fibrous preform corner inserts may be co-molded to a cross-shaped portion tray with resin transfer molding using a thermoset resin. Or the thermoplastic polymer / fiber composite prepreg corner insert can be attached to the cross-section tray by compression molding and curing.